{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:30:04Z","timestamp":1775817004990,"version":"3.50.1"},"reference-count":163,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"European Crohn\u2019s and Colitis Organisation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"DOI":"10.1093\/ecco-jcc\/jjz180","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T08:11:03Z","timestamp":1572682263000},"page":"4-22","source":"Crossref","is-referenced-by-count":1169,"title":["ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment"],"prefix":"10.1093","volume":"14","author":[{"given":"Joana","family":"Torres","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hospital Beatriz \u00c2ngelo, Loures, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6102-6579","authenticated-orcid":false,"given":"Stefanos","family":"Bonovas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"},{"name":"IBD Center, Humanitas Clinical and Research Center, Milan, Italy"}]},{"given":"Glen","family":"Doherty","sequence":"additional","affiliation":[{"name":"Centre for Colorectal Disease, St Vincent\u2019s University Hospital and University College Dublin, Dublin, Ireland"}]},{"given":"Torsten","family":"Kucharzik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Gastroenterology, Hospital L\u00fcneburg, L\u00fcneburg, Germany"}]},{"given":"Javier P","family":"Gisbert","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa [IIS-IP], Universidad Aut\u00f3noma de Madrid, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBEREHD], Madrid, Spain"}]},{"given":"Tim","family":"Raine","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Addenbrooke\u2019s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}]},{"given":"Michel","family":"Adamina","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cantonal Hospital Winterthur, Winterthur, Switzerland"},{"name":"University of Basel, Basel, Switzerland"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IBD Unit, Presidio Columbus Fondazione Policlinico Gemelli Universita Cattolica, Rome, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-2975","authenticated-orcid":false,"given":"Oliver","family":"Bachmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Siloah St. Trudpert Hospital, Pforzheim, Germany"}]},{"given":"Palle","family":"Bager","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark"}]},{"given":"Livia","family":"Biancone","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University \u2018Tor Vergata\u2019 of Rome, Rome, Italy"}]},{"given":"Bernd","family":"Bokemeyer","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice Minden, Minden, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4027-7365","authenticated-orcid":false,"given":"Peter","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Imelda GI Clinical Research Centre, Imelda General Hospital, Bonheiden, Belgium"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-5139","authenticated-orcid":false,"given":"Johan","family":"Burisch","sequence":"additional","affiliation":[{"name":"Gastrounit, Medical Division, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark"}]},{"given":"Paul","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK"}]},{"given":"Alaa","family":"El-Hussuna","sequence":"additional","affiliation":[{"name":"Department of Surgery, Aalborg University Hospital, Aalborg, Denmark"}]},{"given":"Pierre","family":"Ellul","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Mater Dei Hospital, Msida, Malta"}]},{"given":"Cornelia","family":"Frei-Lanter","sequence":"additional","affiliation":[{"name":"Departement of Surgery, Hospital Zollikerberg, Zollikerberg Zurich, Switzerland"}]},{"given":"Federica","family":"Furfaro","sequence":"additional","affiliation":[{"name":"IBD Center, Humanitas Clinical and Research Center, Milan, Italy"}]},{"given":"Christian","family":"Gingert","sequence":"additional","affiliation":[{"name":"Visceral Surgery, Cantonal Hospital Winterthur, Winterthur, Switzerland"},{"name":"Department of Human Medicine, University of Witten\/Herdecke, Witten, Germany"}]},{"given":"Paolo","family":"Gionchetti","sequence":"additional","affiliation":[{"name":"IBD Unit, DIMEC, University of Bologna, Bologna, Italy"}]},{"given":"Fernando","family":"Gomollon","sequence":"additional","affiliation":[{"name":"IBD UNIT, Hospital Cl\u00edico Universitario \u2018Lozano Blesa\u2019; IIS Arag\u00f3n, CIBEREHD, Zaragoza, Spain"}]},{"given":"Marien","family":"Gonz\u00e1lez-Lorenzo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"},{"name":"IBD Center, Humanitas Clinical and Research Center, Milan, Italy"}]},{"given":"Hannah","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Barts Health NHS Trust, Royal London Hospital, London, UK"}]},{"given":"Tibor","family":"Hlavaty","sequence":"additional","affiliation":[{"name":"Fifth Department of Internal Medicine, Comenius University Medical School, Bratislava, Slovakia"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-5235","authenticated-orcid":false,"given":"Pascal","family":"Juillerat","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Inselspital Bern, Bern, Switzerland"}]},{"given":"Konstantinos","family":"Katsanos","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University and Medical School of Ioannina, Ioannina, Greece"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tel-HaShomer Sheba Medical Center, Ramat Gan, Israel; and Sackler Medical School, Tel Aviv, Israel"}]},{"given":"Eduards","family":"Krustins","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, Pauls Stradins Clinical University Hospital, Department of Internal medicine, Riga Stradi\u0146\u0161 university, Riga, Latvia"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4146-4122","authenticated-orcid":false,"given":"Theodore","family":"Lytras","sequence":"additional","affiliation":[{"name":"National Public Health Organization, Athens, Greece"}]},{"given":"Christian","family":"Maaser","sequence":"additional","affiliation":[{"name":"Outpatients Department of Gastroenterology, Hospital L\u00fcneburg, L\u00fcneburg, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics; Institute for Molecular and Cell Biology, University of Porto, Porto, Portugal"}]},{"given":"John","family":"Kenneth Marshall","sequence":"additional","affiliation":[{"name":"Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada"}]},{"given":"P\u00e4r","family":"Myrelid","sequence":"additional","affiliation":[{"name":"Department of Surgery, and Department of Clinical and Experimental Medicine, Link\u00f6ping University, Link\u00f6ping, Sweden"}]},{"given":"Gianluca","family":"Pellino","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, Universit\u00e1 degli Studi della Campania \u2018Luigi Vanvitelli\u2019, Naples, Italy"}]},{"given":"Isadora","family":"Rosa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, IPOLFG, Lisbon, Portugal"}]},{"given":"Joao","family":"Sabino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals, KU Leuven, Leuven, Belgium"}]},{"given":"Edoardo","family":"Savarino","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy"}]},{"given":"Antonino","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Humanitas Clinical and Research Center, Division of Colon and Rectal Surgery, Humanitas University, Milan, Italy"}]},{"given":"Laurents","family":"Stassen","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands"}]},{"given":"Mathieu","family":"Uzzan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, IBD unit, Beaujon Hospital, APHP, Clichy, France"}]},{"given":"Stephan","family":"Vavricka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University Hospital, Z\u00fcrich, Switzerland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium"},{"name":"Department of Chronic Diseases, Metabolism and Ageing, TARGID-IBD, KU Leuven, Leuven, Belgium"}]},{"given":"Janindra","family":"Warusavitarne","sequence":"additional","affiliation":[{"name":"Imperial College London, Department of Surgery and Cancer, St Mark\u2019s Hospital, Department of Gastroenterology, London, UK"}]},{"given":"Oded","family":"Zmora","sequence":"additional","affiliation":[{"name":"Department of Surgery, Shamir Medical Center [Assaf Harofe], Tel Aviv, Israel"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-2968","authenticated-orcid":false,"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"},{"name":"IBD Center, Humanitas Clinical and Research Center, Milan, Italy"}]}],"member":"286","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"key":"2019122411074728900_CIT0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2019122411074728900_CIT0002","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izz092","article-title":"Comparative incidence of inflammatory bowel disease in different age groups in the United States","author":"Keyashian","year":"2019;25:1983\u20131989","journal-title":"Inflamm Bowel Dis"},{"key":"2019122411074728900_CIT0003","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1136\/gutjnl-2019-318936","article-title":"IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology","volume":"68","author":"Jones","year":"2019","journal-title":"Gut"},{"key":"2019122411074728900_CIT0004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","article-title":"Long-term evolution of disease behavior of Crohn\u2019s disease","volume":"8","author":"Cosnes","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"2019122411074728900_CIT0005","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.crohns.2012.10.012","article-title":"Predictive factors for an uncomplicated long-term course of Crohn\u2019s disease: a retrospective analysis","volume":"7","author":"Kruis","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0006","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1136\/gutjnl-2017-314519","article-title":"Early intervention in Crohn\u2019s disease: towards disease modification trials","volume":"66","author":"Danese","year":"2017","journal-title":"Gut"},{"key":"2019122411074728900_CIT0007","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016. Part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0009","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"2019122411074728900_CIT0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","article-title":"European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016. Part 2: surgical management and special situations","volume":"11","author":"Gionchetti","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0011","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.crohns.2014.01.023","article-title":"Diagnostic delay in a French cohort of Crohn\u2019s disease patients","volume":"8","author":"Nahon","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0012","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/ajg.2013.248","article-title":"Diagnostic delay in Crohn\u2019s disease is associated with a complicated disease course and increased operation rate","volume":"108","author":"Schoepfer","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0013","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","article-title":"Risk factors associated with progression to intestinal complications of Crohn\u2019s disease in a population-based cohort","volume":"139","author":"Thia","year":"2010","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0014","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ibd.21719","article-title":"Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease","volume":"18","author":"Vavricka","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2019122411074728900_CIT0015","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease [REACT]: a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"2019122411074728900_CIT0016","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease [CALM]: a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2018","journal-title":"Lancet"},{"key":"2019122411074728900_CIT0017","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD. Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0018","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease [STRIDE]: determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0019","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0021","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/ecco-jcc\/jjx109","article-title":"Research gaps in diet and nutrition in inflammatory bowel disease. a topical review by D-ECCO working group [Dietitians of ECCO]","volume":"11","author":"Sigall-Boneh","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0022","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0023","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz160","article-title":"Perioperative dietary therapy in inflammatory bowel disease","author":"Adamina","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0024","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ajg.2011.71","article-title":"Efficacy of 5-aminosalicylates in Crohn\u2019s disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0025","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3109\/00365528708991929","article-title":"5-Aminosalicylic acid in the treatment of Crohn\u2019s disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa","volume":"22","author":"Rasmussen","year":"1987","journal-title":"Scand J Gastroenterol"},{"key":"2019122411074728900_CIT0026","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","article-title":"Mesalamine capsules for the treatment of active Crohn\u2019s disease: results of a 16-week trial. Pentasa Crohn\u2019s Disease Study Group","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0027","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00004836-199412000-00003","article-title":"A randomized, double-blind, placebo-controlled trial of the oral mesalamine [5-ASA] preparation, Asacol, in the treatment of symptomatic Crohn\u2019s colitis and ileocolitis","volume":"19","author":"Tremaine","year":"1994","journal-title":"J Clin Gastroenterol"},{"key":"2019122411074728900_CIT0028","author":"Ferring Pharmaceuticals","year":"2012"},{"key":"2019122411074728900_CIT0029","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn\u2019s Disease Study [ECCDS]: results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National cooperative Crohn\u2019s disease study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0031","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2019122411074728900_CIT0032","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1097\/MIB.0000000000001158","article-title":"Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn\u2019s disease: a Bayesian network meta-analysis: republished","volume":"23","author":"Coward","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2019122411074728900_CIT0033","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/apt.13190","article-title":"Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine [mesalamine] for Crohn\u2019s disease","volume":"41","author":"Moja","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2019122411074728900_CIT0034","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn\u2019s disease: A meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0035","volume-title":"Budesonide for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev","author":"Rezaie"},{"key":"2019122411074728900_CIT0036","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn\u2019s disease. Canadian Inflammatory Bowel Disease Study Group","volume":"331","author":"Greenberg","year":"1994","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0037","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1572-0241.2002.05835.x","article-title":"Budesonide CIR capsules [once or twice daily divided-dose] in active Crohn\u2019s disease: a randomized placebo-controlled study in the United States","volume":"97","author":"Tremaine","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0038","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.crohns.2012.06.006","article-title":"Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn\u2019s disease: a multicentre, double-blind, randomized, parallel-group Phase II study","volume":"7","author":"Suzuki","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0039","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn\u2019s disease. International Budesonide-Mesalamine Study Group","volume":"339","author":"Thomsen","year":"1998","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0040","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1053\/j.gastro.2010.11.004","article-title":"Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn\u2019s disease","volume":"140","author":"Tromm","year":"2011","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0041","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000484047","article-title":"Efficacy and safety of oral budesonide in patients with active Crohn\u2019s disease in Japan: a multicenter, double-blind, randomized, parallel-group phase 3 study","volume":"2","author":"Yokoyama","year":"2018","journal-title":"Inflamm Intest Dis"},{"key":"2019122411074728900_CIT0042","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ajg.2011.72","article-title":"Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0043","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0044","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2007.03.031","article-title":"Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn\u2019s disease","volume":"132","author":"Selby","year":"2007","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0045","first-page":"CD006792","article-title":"Traditional corticosteroids for induction of remission in Crohn\u2019s disease","author":"Benchimol","year":"2008;2","journal-title":"Cochrane Database Syst Rev"},{"key":"2019122411074728900_CIT0046","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/0016-5085(79)90386-X","article-title":"National Cooperative Crohn\u2019s Disease Study: adverse reactions to study drugs","volume":"77","author":"Singleton","year":"1979","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0047","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn\u2019s disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"2019122411074728900_CIT0048","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0016-5085(93)90709-L","article-title":"Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn\u2019s disease","volume":"105","author":"Ewe","year":"1993","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0049","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0016-5085(74)80166-6","article-title":"Treatment of Crohn\u2019s disease with azathioprine: a controlled evaluation","volume":"66","author":"Klein","year":"1974","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0050","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn\u2019s disease with 6-mercaptopurine. A long-term, randomized, double-blind study","volume":"302","author":"Present","year":"1980","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0051","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/j.1572-0241.2008.02024.x","article-title":"A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn\u2019s disease","volume":"103","author":"Reinisch","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0052","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(71)90598-8","article-title":"Controlled trial of azathioprine in Crohn\u2019s disease","volume":"2","author":"Rhodes","year":"1971","journal-title":"Lancet"},{"key":"2019122411074728900_CIT0053","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S0140-6736(71)90268-6","article-title":"Controlled trial of azathioprine in Crohn\u2019s disease","volume":"2","author":"Willoughby","year":"1971","journal-title":"Lancet"},{"key":"2019122411074728900_CIT0054","first-page":"2203","article-title":"Methotrexate in chronic active Crohn\u2019s disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0055","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0056","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1053\/gast.1996.v110.pm8613046","article-title":"Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial","volume":"110","author":"Oren","year":"1996","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0057","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/ajg.2015.61","article-title":"Erratum: methotrexate in chronic active Crohn\u2019s disease: a double-blind, randomized, Israeli multicenter trial [Am J Gastroenterol 1997;92:2203\u20139]","volume":"110","author":"Oren","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0058","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/ajg.2015.61","article-title":"Corrigendum: methotrexate in chronic active Crohn\u2019s disease: a double-blind, randomized, Israeli multicenter trial","volume":"110","author":"Oren","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0059","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","author":"Mat\u00e9-Jim\u00e9nez","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0060","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1590-8658(03)00372-4","article-title":"Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn\u2019s disease: a randomised, investigator-blind study","volume":"35","author":"Ardizzone","year":"2003","journal-title":"Dig Liver Dis"},{"key":"2019122411074728900_CIT0061","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","article-title":"The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease","volume":"9","author":"van der Woude","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0062","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn\u2019s disease","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2019122411074728900_CIT0063","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2019122411074728900_CIT0064","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0065","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn\u2019s disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"2019122411074728900_CIT0066","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0067","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: a network meta-analysis","volume":"148","author":"Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0068","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: deep remission in biologic and immunomodulator na\u00efve patients with Crohn\u2019s disease a SONIC post hoc analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2019122411074728900_CIT0069","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cgh.2013.10.025","article-title":"Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn\u2019s disease","volume":"12","author":"Colombel","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0070","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0071","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0072","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","article-title":"Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn\u2019s disease","volume":"7","author":"Schreiber","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0073","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn\u2019s disease: a prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0074","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.cgh.2015.06.034","article-title":"Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn\u2019s disease: a meta-analysis of placebo-controlled trials","volume":"13","author":"Jones","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0075","author":"European Medicine Agency. Stelara Ustekinumab","year":"2009"},{"key":"2019122411074728900_CIT0076","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0077","first-page":"CD007572","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn\u2019s disease","volume":"11","author":"MacDonald","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2019122411074728900_CIT0078","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0079","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","article-title":"Efficacy of Ustekinumab for inducing endoscopic healing in patients with Crohn\u2019s disease","volume":"155","author":"Rutgeerts","year":"2018","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0081","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: 3 year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn\u2019s disease","author":"Hanauer","year":"2020;14:23\u201332","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0082","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0083","author":"European Medicine Agency","year":"2014"},{"key":"2019122411074728900_CIT0084","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn\u2019s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0085","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","author":"Sands","year":"2014;3","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0086","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2217\/cer-2017-0041","article-title":"An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn\u2019s disease patients","volume":"7","author":"Kawalec","year":"2018","journal-title":"J Comp Eff Res"},{"key":"2019122411074728900_CIT0087","first-page":"CD000301","article-title":"Corticosteroids for maintenance of remission in Crohn\u2019s disease","author":"Steinhart","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"2019122411074728900_CIT0088","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MIB.0000000000000211","article-title":"Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD?","volume":"21","author":"Kalman","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2019122411074728900_CIT0089","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0091","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"2019122411074728900_CIT0092","first-page":"263","article-title":"European Crohn\u2019s and Colitis Organisation topical review on IBD in the elderly","volume":"11","author":"Sturm","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0093","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1053\/j.gastro.2013.09.035","article-title":"Lymphoma: the b\u00eate noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0094","first-page":"CD003715","article-title":"Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s disease","volume":"9","author":"Akobeng","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2019122411074728900_CIT0095","first-page":"Cd000067","article-title":"Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn\u2019s disease","author":"Chande","year":"2015;10","journal-title":"Cochrane Database Syst Rev"},{"key":"2019122411074728900_CIT0096","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/j.gastro.2005.03.031","article-title":"A randomized, double-blind, controlled withdrawal trial in Crohn\u2019s disease patients in long-term remission on azathioprine","volume":"128","author":"L\u00e9mann","year":"2005","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0097","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(78)92524-2","article-title":"Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn\u2019s disease","volume":"2","author":"O\u2019Donoghue","year":"1978","journal-title":"Lancet"},{"key":"2019122411074728900_CIT0098","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2013.06.009","article-title":"Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn\u2019s disease","volume":"145","author":"Pan\u00e9s","year":"2013","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0099","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/BF01070829","article-title":"A controlled trial of azathioprine in Crohn\u2019s disease","volume":"20","author":"Rosenberg","year":"1975","journal-title":"Am J Dig Dis"},{"key":"2019122411074728900_CIT0100","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.gastro.2013.04.048","article-title":"Early administration of azathioprine vs conventional management of Crohn\u2019s Disease: a randomized controlled trial","volume":"145","author":"Cosnes","year":"2013","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0101","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"2019122411074728900_CIT0102","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0103","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"2019122411074728900_CIT0104","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0105","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011;2","journal-title":"Cochrane Database Syst Rev"},{"key":"2019122411074728900_CIT0106","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2019122411074728900_CIT0107","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0108","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn\u2019s disease","volume":"154","author":"D\u2019Haens","year":"2018","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0109","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2014","journal-title":"Gut"},{"key":"2019122411074728900_CIT0110","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0111","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/14740338.2017.1269169","article-title":"Therapeutic drug monitoring of anti-tumour necrosis factor-\u03b1 agents in inflammatory bowel disease","volume":"16","author":"Mitrev","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2019122411074728900_CIT0112","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1097\/MIB.0000000000001126","article-title":"Therapeutic Drug monitoring to guide infliximab dose adjustment is associated with better endoscopic outcomes than clinical decision making alone in active inflammatory bowel disease","volume":"23","author":"Kelly","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2019122411074728900_CIT0113","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjy076","article-title":"Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study","author":"Guidi","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0114","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/ecco-jcc\/jjy109","article-title":"Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: a systematic review with meta-analysis","volume":"12","author":"Ricciuto","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0115","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2036.2004.01944.x","article-title":"Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn\u2019s disease: increased relapse rate the following year","volume":"19","author":"Vilien","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2019122411074728900_CIT0116","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s10620-014-3419-5","article-title":"Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn\u2019s disease","volume":"60","author":"Wenzl","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2019122411074728900_CIT0117","first-page":"CD012540","article-title":"Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn\u2019s disease","volume":"5","author":"Boyapati","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2019122411074728900_CIT0118","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/apt.14106","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2019122411074728900_CIT0119","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0120","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0121","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/MIB.0000000000001203","article-title":"Systematic review and meta-analysis: adalimumab monotherapy versus combination therapy with immunomodulators for induction and maintenance of remission and response in patients with Crohn\u2019s disease","volume":"23","author":"Chalhoub","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2019122411074728900_CIT0122","doi-asserted-by":"crossref","first-page":"A653","DOI":"10.1016\/S0016-5085(09)63010-9","article-title":"Results from an open-label extension of CHARM: Steroid-free remission in patients with Crohn\u2019s disease who received Adalimumab therapy for at least 3 years","volume":"136","author":"Kamm","year":"2009","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0123","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","article-title":"Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease","volume":"149","author":"Torres","year":"2015","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0124","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0125","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/apt.13547","article-title":"Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis","volume":"43","author":"Kennedy","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2019122411074728900_CIT0126","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ajg.2016.569","article-title":"Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study","volume":"112","author":"Casanova","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2019122411074728900_CIT0127","first-page":"S252","article-title":"Proposal for an anti-tumour necrosis factor-exit strategy based on trough serum level","volume":"10","author":"Helwig","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0128","first-page":"S864","article-title":"Long-term outcome of IBD patients with primary non-response to anti-TNF therapy","volume":"9","author":"Papamichael","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0129","first-page":"205","article-title":"Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy","volume":"117","author":"Hlavaty","year":"2016","journal-title":"Bratisl Lek Listy"},{"key":"2019122411074728900_CIT0130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/00365521.2015.1079924","article-title":"Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation","volume":"51","author":"Bortlik","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"2019122411074728900_CIT0131","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/00365521.2016.1250942","article-title":"Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNF\u03b1-blocking agents","volume":"52","author":"Molander","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"2019122411074728900_CIT0132","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2017.09.061","article-title":"Outcomes 7 years after infliximab withdrawal for patients with Crohn\u2019s disease in sustained remission","volume":"16","author":"Reenaers","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0133","doi-asserted-by":"crossref","first-page":"92","DOI":"10.14740\/gr800w","article-title":"Discontinuation of scheduled infliximab in Crohn\u2019s patients with clinical remission: a retrospective single-center study","volume":"10","author":"Hu","year":"2017","journal-title":"Gastroenterol Res"},{"key":"2019122411074728900_CIT0134","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jgh.13039","article-title":"Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn\u2019s disease in clinical practice","volume":"31","author":"Ampuero","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and Colitis Organisation topical review on treatment withdrawal [\u2018exit strategies\u2019] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0136","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"2019122411074728900_CIT0137","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0138","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0139","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"2019122411074728900_CIT0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40265-017-0842-x","article-title":"Pharmacological approach to the management of Crohn\u2019s disease patients with perianal disease","volume":"78","author":"Bermejo","year":"2018","journal-title":"Drugs"},{"key":"2019122411074728900_CIT0141","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrgastro.2017.104","article-title":"Perianal fistulizing Crohn\u2019s disease: pathogenesis, diagnosis and therapy","volume":"14","author":"Pan\u00e9s","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0142","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/gutjnl-2017-314918","article-title":"Modern management of perianal fistulas in Crohn\u2019s disease: future directions","volume":"67","author":"Kotze","year":"2018","journal-title":"Gut"},{"key":"2019122411074728900_CIT0143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ibd\/izy247","article-title":"Clinical practice guideline for the medical management of perianal fistulizing Crohn\u2019s disease: the Toronto Consensus","volume":"25","author":"Steinhart","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2019122411074728900_CIT0144","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00054725-200303000-00003","article-title":"Treatment of perianal fistulizing Crohn\u2019s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement","volume":"9","author":"Regueiro","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"2019122411074728900_CIT0145","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/apt.13970","article-title":"Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn\u2019s disease","volume":"45","author":"Yarur","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2019122411074728900_CIT0146","first-page":"549","article-title":"Association of induction infliximab levels with clinical response in perianal Crohn\u2019s disease","volume":"11","author":"Davidov","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0147","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"key":"2019122411074728900_CIT0148","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/apt.12499","article-title":"Adalimumab maintains remission of Crohn\u2019s disease after up to 4 years of treatment: data from CHARM and ADHERE","volume":"38","author":"Panaccione","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2019122411074728900_CIT0149","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1365-2036.2010.04466.x","article-title":"The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn\u2019s disease who failed prior infliximab therapy","volume":"32","author":"Lichtiger","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2019122411074728900_CIT0150","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.crohns.2010.07.012","article-title":"Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn\u2019s disease patients with infliximab failure","volume":"4","author":"Echarri","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0151","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.cgh.2012.12.042","article-title":"Long-term outcome of perianal fistulizing Crohn\u2019s disease treated with infliximab","volume":"11","author":"Bouguen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0152","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/S0016-5085(17)30930-7","article-title":"Fistula healing in pivotal studies of ustekinumab in Crohn\u2019s disease","volume":"152","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"2019122411074728900_CIT0153","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.cgh.2018.01.030","article-title":"Efficacy of medical therapies for fistulizing Crohn\u2019s disease: systematic review and meta-analysis","volume":"16","author":"Lee","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019122411074728900_CIT0154","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","article-title":"Efficacy of vedolizumab in fistulising Crohn\u2019s disease: exploratory analyses of data from GEMINI 2","volume":"12","author":"Feagan","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0155"},{"key":"2019122411074728900_CIT0156","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ibd.20608","article-title":"Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn\u2019s disease: a randomized, double-blind, placebo-controlled pilot study","volume":"15","author":"Thia","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"2019122411074728900_CIT0157","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/gutjnl-2013-304488","article-title":"Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn\u2019s disease: a randomised, double-blind, placebo controlled trial [ADAFI]","volume":"63","author":"Dewint","year":"2014","journal-title":"Gut"},{"key":"2019122411074728900_CIT0158","first-page":"864","article-title":"A double-blind trial of azathioprine in Crohn\u2019s disease","volume":"12","author":"Willoughby","year":"1971","journal-title":"Gut"},{"key":"2019122411074728900_CIT0159","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/ecco-jcc\/jjx002.038","article-title":"European Crohn\u2019s and Colitis Organisation topical review on environmental factors in IBD","volume":"11","author":"Maaser","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0160","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ecco-jcc\/jjw055","article-title":"European Crohn\u2019s and Colitis Organisation topical review on prediction, diagnosis and management of fibrostenosing Crohn\u2019s disease","volume":"10","author":"Rieder","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0161","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/ecco-jcc\/jjx010","article-title":"European Crohn\u2019s and Colitis Organisation topical review on transitional care in inflammatory bowel disease","volume":"11","author":"van Rheenen","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0162","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ecco-jcc\/jjw198","article-title":"ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update","volume":"11","author":"Danese","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019122411074728900_CIT0163","author":"European Crohn\u2019s Colitis Organisation ECCO e-Guide","year":"2013"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjz180\/30637374\/jjz180.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/1\/4\/31613532\/jjz180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/1\/4\/31613532\/jjz180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T11:08:37Z","timestamp":1577185717000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/1\/4\/5620479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":163,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,11,11]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,11,11]]}}}